Tapentadol in the management of cancer pain: current evidence and future perspectives

References

• OldenmengerWHGeerlingJIMostovayaIA systematic review of the effectiveness of patient-based educational interventions to improve cancer-related painCancer Treat Rev2018639610329272781
   PubMed Web of Science ®Google Scholar
• van den Beuken-van EverdingenMHHochstenbachLMJoostenEATjan-HeijnenVCJanssenDJUpdate on prevalence of pain in patients with cancer: systematic review and meta-analysisJ Pain Symptom Manage20165161070109027112310
   PubMed Web of Science ®Google Scholar
• von MoosRCostaLRipamontiCINiepelDSantiniDImproving quality of life in patients with advanced cancer: targeting metastatic bone painEur J Cancer201771809427984770
   PubMed Web of Science ®Google Scholar
• CaraceniAHanksGKaasaSEuropean palliative care research collaborative (EPCRC); European association for palliative care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPCLancet Oncol201213e586822300860
   PubMed Web of Science ®Google Scholar
• JaraCdel BarcoSGrávalosCSEOM clinical guideline for treatment of cancer pain (2017)Clin Transl Oncol20182019710729127593
   PubMed Web of Science ®Google Scholar
• MirabileAAiroldiMRipamontiCPain management in head and neck cancer patients undergoing chemo-radiotherapy: clinical practical recommendationsCrit Rev Oncol Hematol20169910010626712589
   PubMed Web of Science ®Google Scholar
• RipamontiCISantiniDMaranzanoEBertiMRoilaFESMO guidelines Working GroupManagement of cancer pain: ESMO clinical practice guidelinesAnn Oncol201223Suppl 7vii13915422997447
   PubMed Web of Science ®Google Scholar
• O’BrienTChristrupLLDrewesAMEuropean Pain Federation position paper on appropriate opioid use in chronic pain managementEur J Pain201721131927991730
   PubMed Web of Science ®Google Scholar
• BreivikHChernyNCollettBCancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudesAnn Oncol20092081420143319244085
   PubMed Web of Science ®Google Scholar
• VellucciRMediatiRDGasperoniSMammucariMMarinangeliFRomualdiPAssessment and treatment of breakthrough cancer pain: from theory to clinical practiceJ Pain Res2017102147215529066928
   PubMed Web of Science ®Google Scholar
• Reis-PinaPLawlorPGBarbosaAAdequacy of cancer-related pain management and predictors of undertreatment at referral to a pain clinicJ Pain Res2017102097210728919809
   PubMed Web of Science ®Google Scholar
• RipamontiCISantiniDMaranzanoEBertiMRoilaFESMO guidelines Working GroupManagement of cancer pain: ESMO clinical practice guidelinesAnn Oncol201223Suppl 7vii139vii15422997447
   PubMed Web of Science ®Google Scholar
• FallonMTNeuropathic pain in cancerBr J Anaesth2013111110511123794652
   PubMed Web of Science ®Google Scholar
• BennettMIRaymentCHjermstadMAassNCaraceniAKaasaSPrevalence and aetiology of neuropathic pain in cancer patients: a systematic reviewPain2012153235936522115921
   PubMed Web of Science ®Google Scholar
• MantyhPWBone cancer pain: from mechanism to therapyCurr Opin Support Palliat Care201482839024792411
   PubMed Web of Science ®Google Scholar
• CurrieGLDelaneyABennettMIAnimal models of bone cancer pain: systematic review and meta-analysesPain2013154691792623582155
   PubMed Web of Science ®Google Scholar
• PortenoyRKAhmedEPrinciples of opioid use in cancer painJ Clin Oncol201432161662167024799466
   PubMed Web of Science ®Google Scholar
• KressHGTapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon?Eur J Pain201014878178320659810
   PubMed Web of Science ®Google Scholar
• LangfordRMKnaggsRFarquhar-SmithPDickensonAHIs tapentadol different from classical opioids? A review of the evidenceBr J Pain201610421722127867511
   PubMed Web of Science ®Google Scholar
• RaffaRBEllingCTzschentkeTMDoes ‘strong analgesic’ equal ‘strong opioid’? Tapentadol and the concept of ‘µ-load’Adv Ther201835101471148430206823
   PubMed Web of Science ®Google Scholar
• PergolizziJVLequangJATaylorROssipovMHColucciDRaffaRBDesigning safer analgesics: a focus on µ-opioid receptor pathwaysExpert Opin Drug Discov2018131096597230175624
   PubMed Web of Science ®Google Scholar
• ImanakaKTominagaYEtropolskiMEfficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related painCurr Med Res Opin201329101399140923937387
   PubMed Web of Science ®Google Scholar
• KressHGKochEDKosturskiHTapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related painPain Physician201417432934325054392
   PubMed Web of Science ®Google Scholar
• KressHGKochEDKosturskiHDirect conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related painEur J Pain20162091513151827062079
   PubMed Web of Science ®Google Scholar
• ImanakaKTominagaYEtropolskiMOhashiHHiroseKMatsumuraTReady conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended releaseClin Drug Investig2014347501511
   PubMed Web of Science ®Google Scholar
• MercadanteSPorzioGFerreraPTapentadol in cancer pain management: a prospective open-label studyCurr Med Res Opin201228111775177923057488
   PubMed Web of Science ®Google Scholar
• SchikowskiAKringsDSchwenkeKTapentadol prolonged release for severe chronic cancer-related pain: effectiveness, tolerability, and influence on quality of life of the patientsJ Pain Res201581825565884
   PubMed Web of Science ®Google Scholar
• CascellaMForteCABimonteSMultiple effectiveness aspects of tapentadol for moderate-severe cancer-pain treatment: an observational prospective studyJ Pain Res20191211712530613160
   PubMed Web of Science ®Google Scholar
• MercadanteSPorzioGAielliFOpioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioidsCurr Med Res Opin201329666166623540512
   PubMed Web of Science ®Google Scholar
• MercadanteSPorzioGAdileCTapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer painCurr Med Res Opin201430102063206824926734
   PubMed Web of Science ®Google Scholar
• ColuzziFRaffaRBPergolizziJTapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone diseaseJ Pain Res2015822923826064064
   PubMed Web of Science ®Google Scholar
• BouhassiraDAttalNAlchaarHComparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4)Pain20051141-2293615733628
   PubMed Web of Science ®Google Scholar
• BrunettiGAPalumboGMoranoGSTapentadol PR for pain syndromes in real life patients with hematological malignancyCardiovasc Hematol Agents Med Chem2016141687427048320
   PubMedGoogle Scholar
• MazzolaRRicchettiFFersinoSErratum: Erratum to: effectiveness of tapentadol prolonged release for the management of painful mucositis in head and neck cancers during intensity modulated radiation therapySupport Care Cancer201624104457527480181
   PubMed Web of Science ®Google Scholar
• GalièEVillaniVTerrenatoIPaceATapentadol in neuropathic pain cancer patients: a prospective open label studyNeurol Sci201738101747175228699105
   PubMed Web of Science ®Google Scholar
• WiffenPJDerrySNaessensKBellRFOral tapentadol for cancer painCochrane Database Syst Rev20159CD011460
   Google Scholar
• TreilletELaurentSHadjiatYPractical management of opioid rotation and equianalgesiaJ Pain Res2018112587260130464578
   PubMed Web of Science ®Google Scholar
• BosilkovskaMWalderBBessonMDaaliYDesmeulesJAnalgesics in patients with hepatic impairment: pharmacology and clinical implicationsDrugs201272121645166922867045
   PubMed Web of Science ®Google Scholar